Compare Piramal Healthcare with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs JUBILANT LIFE SCIENCES - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES JUBILANT LIFE SCIENCES PIRAMAL ENTERPRISES/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x -31.8 13.1 - View Chart
P/BV x 1.1 2.4 44.8% View Chart
Dividend Yield % 2.1 0.6 347.0%  

Financials

 PIRAMAL ENTERPRISES   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
PIRAMAL ENTERPRISES/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs3,303898 367.8%   
Low Rs1,797618 291.0%   
Sales per share (Unadj.) Rs716.5572.0 125.3%  
Earnings per share (Unadj.) Rs79.736.2 220.0%  
Cash flow per share (Unadj.) Rs107.959.5 181.3%  
Dividends per share (Unadj.) Rs28.004.50 622.2%  
Dividend yield (eoy) %1.10.6 184.9%  
Book value per share (Unadj.) Rs1,477.5301.9 489.4%  
Shares outstanding (eoy) m184.45159.28 115.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.61.3 268.6%   
Avg P/E ratio x32.020.9 152.9%  
P/CF ratio (eoy) x23.612.7 185.6%  
Price / Book Value ratio x1.72.5 68.8%  
Dividend payout %35.112.4 282.8%   
Avg Mkt Cap Rs m470,292120,694 389.7%   
No. of employees `0007.82.4 327.2%   
Total wages/salary Rs m22,50419,260 116.8%   
Avg. sales/employee Rs Th16,899.438,120.6 44.3%   
Avg. wages/employee Rs Th2,877.78,058.4 35.7%   
Avg. net profit/employee Rs Th1,879.92,414.3 77.9%   
INCOME DATA
Net Sales Rs m132,15391,108 145.1%  
Other income Rs m3,128357 875.2%   
Total revenues Rs m135,28191,466 147.9%   
Gross profit Rs m66,29017,390 381.2%  
Depreciation Rs m5,2023,709 140.2%   
Interest Rs m44,0972,198 2,006.2%   
Profit before tax Rs m20,11911,840 169.9%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m8,6113,268 263.5%   
Profit after tax Rs m14,7015,770 254.8%  
Gross profit margin %50.219.1 262.8%  
Effective tax rate %42.827.6 155.1%   
Net profit margin %11.16.3 175.7%  
BALANCE SHEET DATA
Current assets Rs m122,74245,848 267.7%   
Current liabilities Rs m310,81020,897 1,487.3%   
Net working cap to sales %-142.327.4 -519.6%  
Current ratio x0.42.2 18.0%  
Inventory Days Days2357 40.6%  
Debtors Days Days3951 76.2%  
Net fixed assets Rs m116,90465,498 178.5%   
Share capital Rs m369159 231.6%   
"Free" reserves Rs m272,16147,930 567.8%   
Net worth Rs m272,53048,089 566.7%   
Long term debt Rs m270,19642,429 636.8%   
Total assets Rs m856,261114,685 746.6%  
Interest coverage x1.56.4 22.8%   
Debt to equity ratio x1.00.9 112.4%  
Sales to assets ratio x0.20.8 19.4%   
Return on assets %6.96.9 98.8%  
Return on equity %5.412.0 45.0%  
Return on capital %12.412.4 100.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,20012,422 122.4%   
Fx outflow Rs m4,88917,227 28.4%   
Net fx Rs m10,312-4,805 -214.6%   
CASH FLOW
From Operations Rs m-115,97511,215 -1,034.1%  
From Investments Rs m-8,265-10,118 81.7%  
From Financial Activity Rs m107,5256,574 1,635.5%  
Net Cashflow Rs m-16,6507,612 -218.7%  

Share Holding

Indian Promoters % 52.9 45.6 116.0%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 4.0 8.7 46.0%  
FIIs % 26.6 21.2 125.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 21.1 78.2%  
Shareholders   93,274 23,815 391.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; Smallcap Stocks Outperform(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended marginally lower.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY21); Net Profit Up 22.1% (Quarterly Result Update)

Aug 25, 2020 | Updated on Aug 25, 2020

For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (3QFY20); Net Profit Up 11.7% (Quarterly Result Update)

Feb 5, 2020 | Updated on Feb 5, 2020

For the quarter ended December 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 6 bn (up 11.7% YoY). Sales on the other hand came in at Rs 38 bn (up 9.1% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (2QFY20); Net Profit Up 18.9% (Quarterly Result Update)

Oct 31, 2019 | Updated on Oct 31, 2019

For the quarter ended September 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 18.9% YoY). Sales on the other hand came in at Rs 23 bn (down 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My Latest Stock Recommendation(Fast Profits Daily)

Oct 9, 2020

How I picked an exciting stock using trends from both the commodity and equity markets.

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

One of the Best Investment Opportunities in the Market Right Now(Fast Profits Daily)

Oct 16, 2020

The one sector that you should be looking at to make good profits.

The Inflection Point for Defence Stocks is Getting Closer(Profit Hunter)

Oct 9, 2020

Few Indian defence companies could use their engineering capabilities to eventually become global leaders.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 22, 2020 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS